Schwab, Molly2009-05-262009-05-262009-04-08https://hdl.handle.net/11299/50344Additional contributor: W. Robert Fleischmann, Jr. (faculty mentor).Genes for IL-15 were transfected into RM-1 (prostate cancer), B16 (melonoma), and 4T1 (breast cancer) cancer cells. The transfected genes consisted of two types, one for the isoform of IL-15 which has a full length leader sequence and is secreted from the cell, and the second for the isoform of IL-15 which has a truncated leader sequence and accumulates in the cytoplasm of the cell. Both kinds of each cancer cell line were cloned, showing that there was little translation of the IL-15 genes in RM-1 and 4T1 cells, and good translation of the IL-15 genes in B16. The vaccine efficacy of the original three cancer cell lines reflected these levels of IL-15. A genetic modification of the IL-15 gene was made to remove the signal peptide of the truncated isoform to make a very short sequence peptide (VSSP-1). The translation of the new genetically modified IL-15 gene was determined by cloning it into all of the cell lines, where it was found to give greater translation of IL-15. The vaccine efficacy for the various IL-15 transfectants of B16 melanoma was determined in mouse tumor studies. The VSSP-1 transfected B16 melanoma vaccine was the most efficacious.en-USCollege of Biological SciencesDepartment of MicrobiologyAcademic Health CenterDepartment of Urologic SurgeryPresentation